I'm on a course at the moment tegretol cr 400 mg novartis "For many investors this is nosebleed territory - especiallysince the stock has opened at twice the IPO price," he added. (Reporting by Jim Finkle; Additional reporting by Nicola Leskeand Olivia Oran in New York, Neha Dimri and SagarikaJaisinghani; in Bangalore; Editing by James Dalgleish andRichard Chang)